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ABSTRACT
The CCAAT box is one of the most common promoter
elements. The evolutionarily conserved heteromeric
factor NF-Y binds this sequence with high affinity and
specificity. By comparing the methylation interference
patterns of different sites, performing electrophoretic
mobility shift assays (EMSA) with IC-substituted oli-
gonucleotides and competition experiments with the
minor groove binding (MGB) drugs distamicin A,
tallimustine and Hoechst 33258 we show that NF-Y
makes key minor groove interactions. Circular per-
mutation assays on four CCAAT boxes, MHC Class 11
Ea, HSP70, e-globin and MSV, indicate that NF-Y is able
to distort the double helix by angles of 62-820,
depending on the site used, and suggest that nucleo-
tides flanking the CCAAT pentanucleotide influence
the degree of bending.
INTRODUCTION
The CCAAT box is a widely distributed regulatory sequence
present in several promoters and enhancers. A computer-assisted
search on 503 eukaryotic promoters indicated that a high
proportion of them (25/30%) harbour this pentanucleotide in the
forward or reverse orientation, often at position -60/80 with respect
to the start site (1). Unlike other elements composed ofpalindromic
sequences, the CCAAT box does not seem to have a symmetry
axis. Several proteins have been reported to bind this or related
sequences (2,3). Among these NF-Y, originally identified as a
factor recognizing the conserved Y box element in the mouse
MHC Class II Ea promoter, has a peculiar and almost absolute
requirement for these five nucleotides and a strong preference for
additional flanks (2,4). Interestingly, the CCAAT consensus
derived by Bucher (PuPuCCAATC/GA/G) fits well with the
optimal NF-Y binding site, but not with the consensus of other
transcription factors that bind CCAAT-related sequences, such as
CTF/NF- I and C/EBP (1).
NF-Y has been shown to be involved in a number of different
systems, in addition to MHC Class II promoters: MSV (2),
HSP70 (3), a-, [- and y-globins (5-7), albumin (8), Thy-1 (9),
a-collagen (10), [-actin (11), IL4 (12,13), Gp9lphox (14),
TSP-I (15), FGF-4 (16), RSV (17) and TK (18). This CCAAT
box binding protein has been identified and, in some cases,
biochemically characterized in several laboratories and, conse-
quently, it has been given different names. Because of the
heteromeric nature of the DNA binding complex, of competition
analysis with Ea Y box oligonucleotides and supershift experi-
ments with anti-NF-Y monoclonal and polyconal antibodies, CP I
(binding to the MLP, [ and y-globin CCAAT box; 3,7), CBF (to
a-collagen; 10), a-CPl (to a-globin; 5), ER (to RSV; 17) and
CBPtk (to human TK; 18) are different acronyms for the same
entity. Therefore it is possible to compare the binding sequences
and methylation interference patterns of all these bonafide NF-Y
binding sites (2,3,5,7,8,11,14-17,19). In all the above-mentioned
promoters functional experiments indicate that the CCAAT box
and, hence NF-Y, plays an important and sometimes essential role
(9,11-16,20-25).
NF-Y is a ubiquitous heteromeric complex formed by at least
three subunits, all necessary for DNA binding (3,5,10): NF-YA
(HAP2/CBF-B) and NF-YB (HAP3/CBF-A), whose genes have
been cloned in a number of species, including maize, Saccharo-
myces cerevisiae and Schizosaccharomyces pombe, sea urchin,
Kluyveromyces lactis (27-34), and the recently discovered
HAP5/CBF-C (35,36). Protein alignments of all the subunits
evidenced highly conserved domains (70% identity) in all species.
Biochemical and genetic analysis dissected the protein-protein and
DNA binding subdomains of HAP3 (34) and HAP2/NF-YA
(37-39). The remarkable degree of conservation between yeast
and man is reminiscent of factors belonging to the basal
transcription machinery: TBP for example, the major determinant
of Pol II positioning, has been shown to bindDNA via a conserved
C-terminal domain that is responsible for making asymmetrical
contacts exclusively with the minor groove and for significantly
bending the double helix by an angle of 800 (40-43). DNA-dic-
tated asymmetry and protein-mediated distorsion of the DNA are
believed to be the rate limiting step in building up a competent
transcription complex (44).
The exact mechanisms of transcriptional activation by NF-Y
are not known. Although the CCAAT box alone is not able to
activate even if multimerized, it appears to increase the activity
of neighbouring enhancer motifs (45,46). In the Ea promoter,
which has no functional TATA box, NF-Y seems to play an
important role in correctly positioning the start site, together with
an initiator element (20,47). The strong -60/80 position prefer-
ence (1) might suggest a structural role in promoter activation.
Because of the evolutionary conservation of the NF-Y subunits
across species and the role that the CCAAT sequence plays in
* To whom correspondence should be addressed
4566 Nucleic Acids Research, 1995, Vol. 23, No. 22
Table 1. List of methylation interference data on NF-Y binding sites
Ea
UAS2UP1
MLP
RSV
a-GLOBIN
y-GLOBIN
P-ACTIN
ALBUMIN
TSP1
Gp9lphox
FGF-4
012345678911
01
TTAACCAATCAGAA
AATlGTTAGTCTT
** 0
TCCACCAATCAACG
AGGTGGTTAGTTGC
o **
O ** *
TAAACCAATCACCT
ATTTGGTTAGTGGA
TCCACCAATCGGCA
AGGTOGTTAGCCGT
00 ** *
CCAGCCAATGAGTA
GGTCGGTTACTCAT
TTGACCAATAGTCT
AACTGGTTATCAGA
GCAGCCAATCAGAG
CGTCGGTTAGTCTC
**
*0
GGAACCAATGAAAT
CCTTGGTTACTTTA
CCGGCCAATGGGCG
GGCCGGTTACCCGC
TTGACCAATGATTA
AACTGGTTACTAAT
CCTGCCAATCAGGG
GGACGGTTAGTCCC
Reference
2
19
diverse promoter contexts in different organisms, we felt that it
was important to know more about how NF-Y binds DNA and
whether, upon binding, it is able to introduce distortions in the
double helix.
MATERIALS AND METHODS
Plasmids
The starting plasmid for the circular permutation assays was
pBend2, described by Aryia et al. (48). The Ea Y 39mer (2) was
inserted by blunt end ligation between the Sail andXbaI sites ofthe
polylinker. Oligonucleotides corresponding to the human HSP70
(CCCCAGCCTCCCTITGGACCAATCAGAGGCCA), MSV
(TfGAACTAACCAATCAG1TCGCT) and human e-globin
(ACACAGGTCAGCCT1GACCAATGAC'1T1F1AAG) CCAAT
boxes were blunt end cloned into the XbaI site.
Electrophoretic mobility shift assay (EMSA)
Binding reactions for NF-Y were performed according to
Chodosh et al. (3) and Mantovani et al. (39), using recombinant
NF-YA (20 ng), purified NF-YB/C (5 ng) and labelled oligonu-
cleotides (10 000 c.p.m.) containing Ea, a-globin and the distal
,y-globin (2,7)CCAAT boxes. EMSA with the AP I site (AGCTT-
GATGAGTCAGCCG) were performed by incubating the la-
belled oligonucleotide in a buffer containing 20% glycerol, 100
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Figure 1. EMSA competition analysis of Y box IC substitution mutants. A
labelled Y box 22mer containing theCCAAT box in reverse orientation (2) was
used as a probe. Oligonucleotides of identical length, but mutated at a single
position, were used as cold competitors. Recombinant NF-YA and purified
NF-YB/C were pre-incubated with the indicated molar excess of IC-substituted
mutants before addition of the labelled oligonucleotide.
mM KCl, 20 mM HEPES, pH 7.9, 1 mM dTT and 0.5 9l (5 jig)
HeLa nuclear extract for 30 min at 250C.
MGBs were dissolved in DMF (N,N-dimethylformamide) at a
10 mM stock concentration (5 mM for tallimustine) and kept at
-20°C; fresh dilutions in water were used for EMSA, either
before addition or after incubation of the labelled oligonucleotide
with the protein (the results were essentially equivalent). For
bending assays, NF-Y was incubated with fragments generated
by the different cuts in each construct used (pBend2Ea, pBend2e,
pBend2HSP70 and Bend2MSV) and end-labelled with polynu-
cleotide kinase. Acrylamide gels (5%, acrylamide/bis acrylamide
ratio 29:1) were run at room temperature. Where indicated an
equivalent amount of mutant NF-YA9, described in Mantovani et
al. (39), was used and also run on 5% gels. Electrophoretic
conditions did not significantly modify the results obtained.
Calculations of bending angles
Location of the points of flexure and amplitudes of the bending
angles were performed according to the method described in
Thompson and Landy (49). Briefly, the mobilities of the
NF-Y-DNA complexes were normalized to the mobilities of the
corresponding free DNA fragments and bending angles calcu-
lated from the ratio between the fastest and the slowest migrating
complexes in EMSA and then by linear interpolation between
points obtained with A-tract DNA standards (49), according to
the formula gM/DE = cos a/2, where gm is the relative mobility
of the complex exactly in the middle, lE is the relative mobility
of the complex at the end of the fragment and at is the angle of
deviation. To determine bending centres the normalized mobility
of each NF-Y-DNA complex was plotted as a function of the
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Figure 2. Specificity ofMGBs-DNA interactions. (A) Lack ofEMSA inhibition by MGBs on the API site. A labelled API site corresponding to the collagenase TRE
(TPA-responsive element) was incubated with 5 gg HeLa nuclear extract either in the absence (lane 1) or in the presence of increasing concentrations of three MGB
drugs: distamycin A (lanes 2-5), tallimustine (lanes 6-9) and Hoechst 33258 (lanes 10-13). (B) A labelled Y box oligonucleotide was incubated with the indicated
amounts of MGBs in the absence of NF-Y protein.
distance between the centre of the CCAAT sequence and the end
of the DNA fragment. The bend was determined as the position
at which the NF-Y-DNA complex was at a minimum.
RESULTS
Comparison of the methylation interference patterns of
NF-Y on different sites
Because of its wide distribution, high affmnity and specificity for
CCAAT box sequences, several investigators identified NF-Y in
biochemical characterizations of CCAAT box binding proteins
involved in the regulation of different promoters. In many such
studies methylation interference assays were performed to
precisely pinpoint the nucleotides involved in protein-DNA
interactions. This assay involves treatment of the target oligonu-
cleotide with dimethylsulfate, which methylates Gs at the N7
position and As at the N3 position, separation of the free from the
bound oligonucleotides by EMSA and identification of purine
residues necessary for stable binding as missing bands in a
sequencing gel. Such experiments not only give precise informa-
tion about the sequence requirements of the protein, but also
suggest whether the protein contacts the major or the minor groove
(50): protection of Gs indicates that the protein is contacting the
major groove, while a missing A is indicative of minor groove
binding.
Table 1 lists the high affinity NF-Y binding sites for which
methylation interference data are available. They recognize a single
DNA binding factor, variously terned in different laboratories,
whose identity with NF-Y has been established by competition with
an Ea Y box oligonucleotide and/or with anti-NF-Y antibodies
(5-18). The protected nucleotides in methylation interference
patterns are indicated as asterisks and open circles represent partial
protection. Several common features are evident.
The two purines at positions +1 and +2 are protected only ifone
(a- and y-globin and Gp91) or two Gs (TSP1) are present.
Adenines are never protected, whether single (UAS2UPI, RSV,
a-globin, y-globin, [3-actin and Gp91phox) or double (Ea, albumin
and MLP),
The two Gs on the bottom strand at positions +3/+4 and the two
As on the top strand at positions +5/+6 are always protected (with
the exception of the +3 G in FGF-4 and the +5 A in Ea).
The A on the bottom strand at position +7 is completely (MLP,
a-globin, y-globin, [8-actin, albumin, TSP1, Gp9l and FGF-4) or
partially protected (Ea, UAS2UP1 and RSV).
Protection ofGs on the top strand at positions +8/+10 is evident
in some sites (RSV, TSP1, Ea and albumin) but not in others,
whereas an A at position +9 is usually protected (Ea, UAS2UP1,
[-actin, albumin, Gp9l and MLP), the only exceptions being
a-globin and FGF-4. On the bottom strand such positions are
never protected, despite the presence of several Gs.
Overall these data suggest that: (i) the NF-Y binding site extends
over one turn ofthe double helix (10.1-I bp) and only in MLP, RSV
and FGF-4 can partial protections outside the consensus core be
scored; (ii) the NF-Y binding site can be tentatively separated into
two halves. The left hand PuPuCC (+1/+4) would contact the
protein through the major groove, since Gs, but not As, are
protected on both the top and bottom strands. On the right hand
(+5/+9) NF-Y would make essential contacts in the minor groove
A
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Figure 3. Selective EMSA inhibition by MGBs on NF-Y binding sites. Labelled oligonucleotides corresponding to the Ea Y box (A), the y-globin distal (B) and the
a-globin CCAAT sequences (C) were pre-incubated with the indicated concentrations ofdistamycin A, tallimustine and Hoechst 33258, before addition of recombinant
NF-YA and purified NF-YB/C. AT-fich sequences susceptible to MGB binding are underlined for the three oligonucleotides used.
as well, since As tend to be highly protected both on the top (+5,
+6 and +9) and on the bottom strands (+7).
IC substitutions identify essential and non-essential
nucleotides
To gain further information on the latter point we exploited the
fact that hydrogen bonding on purine and pyrimidine rings in
inosine-C pairs resemble G-C in the major groove and A-T in the
minor grove (50) and therefore inosine-cytosine mutagenesis can
give informations regarding major/minor groove contacts. This
feature was successfully used to study the modality of TBP
binding to the AdML TATA box (51,52). An oligonucleotide
containing IC nucleotide pairs instead of ATs allowed normal
interaction with TBP, an indication that only the minor groove
was involved in protein-DNA interactions. Such findings were
later fully confirmed by crystallographic studies. Similarly,
TCF-1 and SRY were also shown to interact mainly with the
minor groove (53). It should be noted that the TBP consensus is
relatively loose (54-56) and no single nucleotide was shown to
be absolutely essential. In the case ofNF-Y the sequence-specific
requirements are quite high, since saturation mutagenesis studies
on a number of different sites clearly established the need for
every single base pair of the CCAAT pentanucleotide
(2,10,11,17,22) with the exception of the +7 T in two cases, where
a C can be found instead (19,57). We introduced IC substitutions
into each single nucleotide of the Ea CCAAT box oligonucleotide
and performed competition EMSA analysis using a labelled Y box
22mer and purified NF-Y (2,39). Binding to an IC substitution
mutant would indicate minor groove binding, while lack of
binding would suggest either major groove binding or selective
recognition in the minor groove of a specific determinant in the
A/T pair.
Figure 1 shows the results of such competition experiments.
Even at a very high molar excess (500-fold) no competition was
essentially observed with -521C, -55IC and -561C mutant
oligonucleotides, while -541C and -571C competed essentially as
did the wild-type oligonucleotide. An intermediate situation was
evident for the -531C mutation, which competed with a 10-fold
lower affinity. Evidence from the methylation interference
experiments lends strong support to the idea that the two Cs at the
+3/+4 positions are contacted in the major groove, so lack of
competition of-521C and, partially, of-531C, confirm these data.
Normal binding of -541C strongly points to minor groove
contacts, since other mutations at this position alter binding
severely (2,17,22). -55IC and -561C are more puzzling, because
if the minor groove is indeed implicated, it has to harbour enough
sequence-specific information to account for the almost absolute
requirement for these two base pairs. Alternatively, in contradic-
tion of the methylation interference data, this result could indicate
that only the major groove is implicated. Finally, good competi-
tion of -571C was not surprising, given the presence in high
affinity binding sites of either a C (Ea), an A (,y-globin) or a G
(ca-globin, albumin).
Effects of minor groove binders on NF-Y binding
To discriminate between the two possibilities emerging from the
competition experiments with the -551C and -561C substitution
mutants we decided to use small drugs known to bind specifically
in the minor groove (minor groove binders or MGBs) in EMSA
inhibition experiments. Distamycin A is a sequence-specific DNA
a** .. A.&-&- -4-
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binding compound which recognizes AT-rich stretches by
interacting non-covalently with the narrower minor groove
associated with AT pairs (58). In order to bind DNA it needs only
four ATs. The benzoyl nitrogen mustard tallimustine, an alkylating
derivative ofdistamycin A, shows powerful anti-tumor activity and
binds similar sequences with a 3-fold lower affinity with respect to
distamycin A (59). Hoechst 33258 is another MGB showing
preference for AT stretches (60). In control experiments to verify
the specificity of such compounds we incubatedMGBs at different
concentrations with a known major groove binding protein, the
Fos/Jun-API complex, and the respective target site (collagenase
TRE; see 61). Figure 2A shows that no decrease in the intensity
of the API complex is seen, even at high concentrations of the
three drugs. The same result was obtained employing the NFkB
site (data not shown) and is in line with previous published
observations on another DNA binding protein, SPI (62). In
addition, we performed EMSA using the Ea Y box oligonucleo-
tide, which contains two AT-rich stretches, and high concentrations
of the three MGBs in the absence of NF-Y Figure 2B indicates
that under the NF-Y binding and electrophoretic conditions used,
only tallimustine shows a light smear at 20 ,uM, an indication of
possible dissociation during electrophoresis.
We then felt confident that we could employ these compounds
to ascertain whether the AAT right half of the NF-Y site is
contacted in the minor groove. For this purpose we decided to use
three high affinity sites, Ea and a- and y-globin, each containing
the core CCAAT sequence, but differing considerably in the
flanking sequences. While the Ea oligonucleotide contains several
binding sites for MGBs outside the CCAAT pentanucleotide,
y-globin, having an A at position +8, only has the AATA stretch
(+5/+8) as a possible target for MGB drugs. On the other hand,
the a-globin oligonucleotide does not have any run of four
consecutive ATs, hence it could not be bound by such compounds.
We used different concentrations ofMGBs in EMSA with the
above-mentioned oligonucleotides. The results shown in Figure
3A indicate that NF-Y binding to the AT-rich Ea oligonucleotide
is completely inhibited at 2 jM distamycin A and at somewhat
higher concentrations of tallimustine and Hoechst 33258. Similar
data were obtained with the y-globin oligonucleotide (Fig. 3B);
inhibition is quite strong (90%) at 2 ,uM and complete at 20 jM
for the other two MGBs. Finally, the a-globin oligonucleotide
shows modest inhibition only at the highest distamycin A
concentration and not at all with the other two MGBs (Fig. 3C).
The differences between the a- and y-globin oligonucleotides in
the inhibition profiles indicate that NF-Y binding to the AATA
sequence, which is the only target for MGBs on the latter
oligonucleotide, is strongly diminished when the minor groove is
occupied by the drugs. Interestingly, strong inhibition on the Ea
oligonucleotide, which can only be bound by MGBs outside the
core CCAAT, suggests that minor groove contacts in the flanking
sequences might also be important for NF-Y binding, a notion
that was previously suggested by some of the mutagenesis studies
(2).
NF-Y introduces distortions in the double helix
It is known that several transcription factors introduce flexures in
the DNA helix upon binding to their target sites (see 63 for a
review). Minor groove binding proteins TBP andHMG box-con-
taining LEFI, HMG1 and SRY introduce large directed distor-
tions (64,65). We therefore wished to verify whether NF-Y could
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Figure 4. Circular permutation assays of NF-Y. The Y box 39mer was cloned
in the bending plasmid pBend2 in the reverse orientation. Six restriction
enzymes (indicated in the scheme) were used to generate the 158 bp fragments
used in the EMSA. We used recombinant wild-type NF-YA long form (lanes
1-6) and recombinant NF-YA9 mutant, containing only the conserved HAP2
homology region (lanes 7-12), together with purified NF-YB/C.
also bend DNA by performing a circular permutation assay. We
cloned the Y box oligonucleotide (2) into the pBend2 plasmid
(48) cut with different restriction enzymes, generating fragments
of identical length (158 bp) in which the NF-Y binding site is
located at different positions with respect to the ends of the
fragment, and used them in EMSA with purified NF-YB/C and
recombinant NF-YA. Results of such experiments are shown in
Figure 4. Fragments in which the Y box is positioned in an
eccentric position, BamHI and Spel on the left side and Asp718
and Bglll on the right side, show a faster mobility of the NF-Y
complex compared with the two central fragments, EcoRV and
Stul. Using an NF-YA mutant containing only the 57 amino acids
sufficient for subunit interaction andDNA binding (YA9; see 39)
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Tible 2. Mapping of the bending centre of different NF-Y binding sites
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Figure 5. Circular pennutation assay with HSP70, MSV and e-globin CCAAT
sites. The BamHl (lanes 1, 4 and 7), EcoRV (lanes 2,5,8) and BgllI (lanes 3,6,9)
fragments of pBend2HSP70 (lanes 1-3), pBend2e (lanes 4-7) and
pBend2MSV (lanes 7-9) were incubated with NF-YA9 and NF-YB/C.
DISCUSSION
very similar results were obtained (Fig. 4B, lanes 1-6). Calcula-
tion of the distortion angles induced by NF-Y and NF-YA9
indicated values of 620 and 66° respectively. In both cases the
bending centre was close to the core CCAAT sequence, as
measured by plotting the mobilities of the NF-Y-DNA com-
plexes as a function of the position of the restriction sites relative
to the Y box sequence (Table 2). Incidentally, migration of the
free fragments is compatible with a slight degree of intrinsic DNA
bending (see the free DNA fragments in Fig. 4).
To further substantiate these results we verified whether other
CCAAT boxes embedded in different sequences would also be
bent by NF-Y We employed sites that have been shown to have
different affmiities for NF-Y: the human HSP70 (high affmiity;
R.Mantovani, unpublished), the MSV (medium affinity; 2) and
the e-globin (low affinity; A.Ronchi and R.Mantovani, in
preparation) sites. As shown in Figure 5, NF-Y clearly distorts the
DNA molecules, by 800 and 820 respectively for the wild-type
NF-Y and NF-YA9 proteins used, similar among them, but slightly
different from the values obtained with the Ea Y box. In all these
experiments the flexure centre is positioned in the CCAAT
pentanucleotide (Table 2). The sharper angles observed with these
probes (20° difference) are most likely due to sequences
surrounding the conserved AACCAAT sequence.
Taken together, these results indicate that NF-Y is able to
significantly bend DNA upon binding and that the Q-rich and
S/T-rich regions of NF-YA are largely expendable. The centre of
distortion is located in the conserved CCAAT region (see Table 2)
and the nature of the neighbouring sequences remarkably
influences the degree of bending.
In this report we have investigated some of the in vitro binding
features of the CCAAT box binding protein NF-Y and reached a
few conclusions that can be summarized in the following points.
NF-Y binds both in the major and minor grooves of the double
helix, based on the methylation interference patterns of several
bonafide NF-Y binding sites, on competition experiments with
three MGBs and, partially, on IC substitution mutagenesis. MGB
experiments with the Ea and y-globin CCAAT boxes show that
inhibitory concentrations are similar to those required to prevent
interaction of TBP with the minor groove of TATA sequences
(62,66). This assay appears to be rather specific, since proteins
that recognize the major groove, such as Fos/Jun family members
or SP1, are not inhibited by these compounds (62,67). Crystallo-
graphic studies on several sequence-specific DNA binding
proteins interacting with their target sequence determined that
contacts are made only in the major groove, where most of the
determinants allowing proteins to discriminate between the
different nucleotides are located (68). Proteins that bind DNA as
dimers, such as members of the leucine zipper and HLH families,
are included in the list. However, notable exceptions are
homeodomain (HD) proteins, recognizing both the major and,
through the N-terminal part, the minor groove, HMG proteins and
TBP, which exclusively makes sequence-specific contacts in the
minor groove (40-43).
It has recently been shown that MGBs can inhibit TBP binding
and basal in vitro transcription (62). Here we show that NF-Y
binding can also be prone to MGB interference at similar
concentrations, but only at selected sites, indicating that even
within a single DNA binding protein inhibitory doses can vary
I.
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over two orders of magnitude and implying a remarkable degree
of selectivity for these drugs. It will be interesting to test the role
of such compounds in functional CCAAT-dependant assays.
IC substitution experiments prove that despite minor groove
binding, the +6 A and +7 T retain remarkable sequence
specificity. Other minor groove binding factors, like TBP and
HMG, are far less susceptible to single nucleotide changes
(53-56), in fact, it has been shown that the entire TATA box can
be mutated into IC sequences and still bind TBP normally
(51,52). This is certainly not possible for NF-Y, which has a high
degree of discriminatory power not only in the major groove, but
for minor groove constituents as well.
Both methylation interference and competition with MGBs
suggest that the NF-Y binding site can be divided in two halves:
the 5'-part (PuPuCC) is in contact with the major groove, while
the 3'-part (AATC/AG/G) interacts with the minor groove. NF-Y
seems to lie on one side, contacting at least one full turn of the
double helix. The apparent asymmetry of the CCAAT box
probably mirrors asymmetric contact points on the NF-Y
heteromeric protein complex. Perhaps the best known example of
an asymmetric binding site is represented by the TATA box: TBP
however, thanks to two direct repeats present in the C-terminal
conserved domain, contains a remarkable symmetry in the
protein surfaces presented for association with other polypeptides
(40-43). The polarity comes from the non-conserved N-terminal
region. No repeat is found in the DNA binding domains of the
three NF-Y subunits contacting DNA. We can conclude that
asymmetry is the rule for this transcription factor, both at the
DNA and at the protein levels. This finding could imply important
functional consequences. The CCAAT box, in fact, is present in
both the forward (globins, albumin and [-actin) and reverse
orientations (MHC Class II), statistically equally well represented
(1). Moreover, the distance between this element and the binding
sites of several other factors in different promoters is important,
including in MHC Class II promoters. In some cases NF-Y seems
to favour the binding of transcription factors to nearby sequences:
RFX to the Dra X box (69) and C-EBP to the albumin D box (70).
The polarity of NF-Y binding could then be essential for
protein-protein interactions and influence the general promoter
architecture. This might indicate that different parts of the complex
are specifically able to contact different classes of activators.
As a result of NF-Y binding the DNA is distorted to a degree
that is somewhat dependant on the composition of neighbouring
sequences, varying between 620 and 820. The centre of the
flexure is the CCAAT box, itself a sequence that seems to be to
some extent intrinsically bent. The bending capacity is shared by
a number of other transcription factors and seems to be a common
theme among proteins that do not have strong activating surfaces
(40-43,53,64,65). The degree of bending, which is relatively
large compared with other transcription factors, such as ER,
Ig/IBP, LAP and OCT 1, all inducing angles between 300 and 500,
resembles more the sharper angles generated by TBP (800;
40-43), YY1 (78°; 71) and HMG (75/130°; 64,65). Such
proteins are known to play a general role in the organization of the
three-dimensional promoter structure, rather than directly activat-
ing transcription (40-43,64,66,71). NF-Y is not able to activate
alone, but rather needs other activators nearby (45,46). It is
conceivable that this cooperative function is in part elicited by
indirect facilitation of protein-protein interactions, brought about
by NF-Y-induced DNA distortions at the CCAAT box. Moreover,
several promoters, including y-globin, gp91phox, IL4, DNA Pol
a and TK (7,13,14,18), contain multiple NF-Y binding sites and
therefore are probably prone to multiple NF-Y-dependent levels
of organization.
The Q-rich and S/T-rich domains of NF-YA are expendable for
DNA bending and do not seem to significantly influence the
degree of distortion. The phylogenetically conserved subunit
interaction and DNA binding regions of the NF-Y components
are necessary and sufficient, a feature found in some, but not all
DNA binding proteins: Fos/Jun and other members of the leucine
zipper family, for example, show a clear influence of other protein
domains on the degree of DNA flexure (72,73).
If protein sequences outside the conserved HAP homology
domains are neutral, DNA sequences flanking the CCAAT box
appear to play a role in determining the amplitude of the angle.
The Ea Y box sequences flanked by AT-rich runs reduce the
angle, possibly by generating intrinsic bends at both the 5'- and
3'-ends of the pentanucleotide. Indeed, we note that such bends
are in agreement with the rules determined by the studies of Koo
et al. (74). On the other hand, when embedded in GC-rich
stiffening sequences NF-Y induces wider angles. Surrounding
nucleotides, without making direct contacts with the protein, are
probably far from being neutral in terms of the overall effect of
NF-Y binding on promoter conformation. It is known that in all
MHC Class II genes the distance between the X and the Y box is
invariant in length, but variable in sequence (75). We note that
AT-rich stretches are conserved at both the 5'-end, between X and
Y, and the 3'-end of the Y box, suggesting that they are important
for the correct spatial relationships between NF-Y and X box
binding activators on one side (69) and, possibly, between NF-Y
and general transcription factors responsible for Pol II positioning
on the other.
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